Response to Autologous HSCT Durable for Patients With Systemic Sclerosis

TUESDAY, Nov. 3, 2026 (HealthDay News) -- For patients with systemic sclerosis undergoing autologous hematopoietic stem-cell transplantation (HSCT), long-term follow-up indicates durable response, with 60 percent progression-free survival at 10 years, according to a study published online Oct. 29 in The Lancet Rheumatology.Joerg Henes, M.D., Ph.D., from the University Hospital Tübingen in Germany, and colleagues conducted a cohort study involving patients with systemic sclerosis who had undergone their first autologous HSCT. Follow-up data were obtained from 13 participating centers, which completed a yearly case report form for each patient alive after two years and up to 10 years after autologous HSCT.The long-term extension study included 80 patients with systemic sclerosis who had an autologous HSCT between Dec. 4, 2012, and Jan. 19, 2016, with a median follow-up of 9.2 years. The researchers found that progression-free survival was 81, 72, and 60 percent at two, five, and 10 years, respectively. Overall, 18 patients died during the study, with causes of death including autologous HSCT-related causes, disease progression, post-autologous HSCT malignancy, and late serious infection in five, nine, two, and two patients, respectively (6, 11, 3, and 3 percent, respectively). Over 10 years, 34 patients (43 percent) maintained remission without immunosuppressive treatment."These long-term findings help clinicians understand the durability of systemic sclerosis disease control following autologous hematology cell transplantation, while highlighting the risks that require continued monitoring," Henes said in a statement.Several authors disclosed ties to the pharmaceutical industry.Abstract/Full Text.Sign up for our weekly HealthDay newsletter

Response to Autologous HSCT Durable for Patients With Systemic Sclerosis

Related Stories

Inpatient Rehab, Nursing Facility Or Home? How To Choose The Right Rehab After A Hospital Stay

Patient Reps on FDA Committees Often Have Pharma Ties

FDA Patient, Consumer Reps Often Tied To Pharma-Funded Groups

GLP-1s Show Benefit For Kids With Type 2 Diabetes